Literature DB >> 20154216

STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells.

Inbal Hazan-Halevy1, David Harris, Zhiming Liu, Jie Liu, Ping Li, Xiaomin Chen, Sreejesh Shanker, Alessandra Ferrajoli, Michael J Keating, Zeev Estrov.   

Abstract

Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western hemisphere, but its pathogenesis is still poorly understood. Constitutive tyrosine phosphorylation (p) of signal transducer and activator of transcription (STAT) 3 occurs in several solid tumors and hematologic malignancies. In CLL, however, STAT3 is constitutively phosphorylated on serine 727, not tyrosine 705, residues. Because the biologic significance of serine pSTAT3 in CLL is not known, we studied peripheral blood cells of 106 patients with CLL and found that, although tyrosine pSTAT3 was inducible, serine pSTAT3 was constitutive in all patients studied, regardless of blood count, disease stage, or treatment status. In addition, we demonstrated that constitutive serine pSTAT3 translocates to the nucleus by the karyopherin-beta nucleocytoplasmic system and binds DNA. Dephosphorylation of inducible tyrosine pSTAT3 did not affect STAT3-DNA binding, suggesting that constitutive serine pSTAT3 binds DNA. Furthermore, infection of CLL cells with lentiviral STAT3-small hairpin RNA reduced the expression of several STAT3-regulated survival and proliferation genes and induced apoptosis, suggesting that constitutive serine pSTAT3 initiates transcription in CLL cells. Taken together, our data suggest that constitutive phosphorylation of STAT3 on serine 727 residues is a hallmark of CLL and that STAT3 be considered a therapeutic target in this disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20154216      PMCID: PMC2918366          DOI: 10.1182/blood-2009-10-230060

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  Aberrant morphology, proliferation, and apoptosis of B-cell chronic lymphocytic leukemia cells.

Authors:  Carlos E Bueso-Ramos; Alessandra Ferrajoli; L Jeffrey Medeiros; Michael J Keating; Zeev Estrov
Journal:  Hematology       Date:  2004-08       Impact factor: 2.269

2.  Validating Stat3 in cancer therapy.

Authors:  James E Darnell
Journal:  Nat Med       Date:  2005-06       Impact factor: 53.440

3.  Sensitization of IL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity.

Authors:  Jelena Tomic; Dionne White; Yonghong Shi; Jenny Mena; Caitlin Hammond; Liwei He; Richard L Miller; David E Spaner
Journal:  J Immunol       Date:  2006-03-15       Impact factor: 5.422

4.  In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells.

Authors:  Bradley T Messmer; Davorka Messmer; Steven L Allen; Jonathan E Kolitz; Prasad Kudalkar; Denise Cesar; Elizabeth J Murphy; Prasad Koduru; Manlio Ferrarini; Simona Zupo; Giovanna Cutrona; Rajendra N Damle; Tarun Wasil; Kanti R Rai; Marc K Hellerstein; Nicholas Chiorazzi
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

5.  Extracellular signal-dependent nuclear import of STAT3 is mediated by various importin alphas.

Authors:  Ryosuke Ushijima; Naoko Sakaguchi; Arihiro Kano; Atsushi Maruyama; Yoichi Miyamoto; Toshihiro Sekimoto; Yoshihiro Yoneda; Kenji Ogino; Taro Tachibana
Journal:  Biochem Biophys Res Commun       Date:  2005-05-13       Impact factor: 3.575

6.  miR-15 and miR-16 induce apoptosis by targeting BCL2.

Authors:  Amelia Cimmino; George Adrian Calin; Muller Fabbri; Marilena V Iorio; Manuela Ferracin; Masayoshi Shimizu; Sylwia E Wojcik; Rami I Aqeilan; Simona Zupo; Mariella Dono; Laura Rassenti; Hansjuerg Alder; Stefano Volinia; Chang-Gong Liu; Thomas J Kipps; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-15       Impact factor: 11.205

7.  VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance.

Authors:  Y K Lee; T D Shanafelt; N D Bone; A K Strege; D F Jelinek; N E Kay
Journal:  Leukemia       Date:  2005-04       Impact factor: 11.528

8.  STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3.

Authors:  Ling Liu; Kevin M McBride; Nancy C Reich
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-26       Impact factor: 11.205

9.  Activation of signal transducer and activator of transcription 3 through a phosphomimetic serine 727 promotes prostate tumorigenesis independent of tyrosine 705 phosphorylation.

Authors:  Haiyan R Qin; Han-Jong Kim; Joon-Young Kim; Elaine M Hurt; George J Klarmann; Brian T Kawasaki; Maria A Duhagon Serrat; William L Farrar
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

10.  Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3.

Authors:  Kenneth Leslie; Cynthia Lang; Geeta Devgan; Janeen Azare; Marjan Berishaj; William Gerald; Young Bae Kim; Keren Paz; James E Darnell; Christopher Albanese; Toshiyuki Sakamaki; Richard Pestell; Jacqueline Bromberg
Journal:  Cancer Res       Date:  2006-03-01       Impact factor: 12.701

View more
  102 in total

1.  Mouse hematopoietic cell-targeted STAT3 deletion: stem/progenitor cell defects, mitochondrial dysfunction, ROS overproduction, and a rapid aging-like phenotype.

Authors:  Charlie Mantel; Steven Messina-Graham; Akira Moh; Scott Cooper; Giao Hangoc; Xin-Yuan Fu; Hal E Broxmeyer
Journal:  Blood       Date:  2012-06-04       Impact factor: 22.113

2.  Up-Regulation of CX3CL1 via STAT3 Contributes to SMIR-Induced Chronic Postsurgical Pain.

Authors:  Yijia Shen; Dai Li; Bo Li; Peng Xi; Yun Zhang; Youshui Jiang; Yehao Xu; Hui Chen; Yuanchang Xiong
Journal:  Neurochem Res       Date:  2018-01-08       Impact factor: 3.996

3.  Benzoxathiol derivative BOT-4-one suppresses L540 lymphoma cell survival and proliferation via inhibition of JAK3/STAT3 signaling.

Authors:  Byung Hak Kim; Yun Sook Min; Jung Sook Choi; Gyeong Hun Baeg; Young Soo Kim; Jong Wook Shin; Tae Yoon Kim; Sang Kyu Ye
Journal:  Exp Mol Med       Date:  2011-05-31       Impact factor: 8.718

4.  Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3.

Authors:  Xavier Badoux; Carlos Bueso-Ramos; David Harris; Ping Li; Zhiming Liu; Jan Burger; Susan O'Brien; Alessandra Ferrajoli; Michael J Keating; Zeev Estrov
Journal:  Hum Pathol       Date:  2011-07-05       Impact factor: 3.466

5.  STAT3 Inhibition by Microtubule-Targeted Drugs: Dual Molecular Effects of Chemotherapeutic Agents.

Authors:  Sarah R Walker; Mousumi Chaudhury; David A Frank
Journal:  Mol Cell Pharmacol       Date:  2011-01-01

6.  STAT3 mutations are present in aggressive B-cell lymphomas including a subset of diffuse large B-cell lymphomas with CD30 expression.

Authors:  Robert S Ohgami; Lisa Ma; Ahmad Monabati; James L Zehnder; Daniel A Arber
Journal:  Haematologica       Date:  2014-05-16       Impact factor: 9.941

7.  Activation of the B-cell receptor successively activates NF-κB and STAT3 in chronic lymphocytic leukemia cells.

Authors:  Uri Rozovski; David M Harris; Ping Li; Zhiming Liu; Preetesh Jain; Ivo Veletic; Alessandra Ferrajoli; Jan Burger; Philip Thompson; Nitin Jain; William Wierda; Michael J Keating; Zeev Estrov
Journal:  Int J Cancer       Date:  2017-08-04       Impact factor: 7.396

8.  Cellular calibrators to quantitate T-cell receptor excision circles (TRECs) in clinical samples.

Authors:  Divya Punwani; Diana Gonzalez-Espinosa; Anne Marie Comeau; Amalia Dutra; Evgenia Pak; Jennifer Puck
Journal:  Mol Genet Metab       Date:  2012-09-21       Impact factor: 4.797

9.  Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells.

Authors:  Ping Li; David Harris; Zhiming Liu; Jie Liu; Michael Keating; Zeev Estrov
Journal:  PLoS One       Date:  2010-07-29       Impact factor: 3.240

10.  Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia.

Authors:  Preetesh Jain; Rashmi Kanagal-Shamanna; William Wierda; Michael Keating; Nawid Sarwari; Uri Rozovski; Philip Thompson; Jan Burger; Hagop Kantarjian; Keyur P Patel; L Jeffrey Medeiros; Rajyalakshmi Luthra; Zeev Estrov
Journal:  Am J Hematol       Date:  2016-08-22       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.